文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

序贯免疫疗法:走向自身免疫病的治愈之路。

Sequential immunotherapy: towards cures for autoimmunity.

机构信息

Bristol Myers Squibb, New York, NY, USA.

出版信息

Nat Rev Drug Discov. 2024 Jul;23(7):501-524. doi: 10.1038/s41573-024-00959-8. Epub 2024 Jun 5.


DOI:10.1038/s41573-024-00959-8
PMID:38839912
Abstract

Despite major progress in the treatment of autoimmune diseases in the past two decades, most therapies do not cure disease and can be associated with increased risk of infection through broad suppression of the immune system. However, advances in understanding the causes of autoimmune disease and clinical data from novel therapeutic modalities such as chimeric antigen receptor T cell therapies provide evidence that it may be possible to re-establish immune homeostasis and, potentially, prolong remission or even cure autoimmune diseases. Here, we propose a 'sequential immunotherapy' framework for immune system modulation to help achieve this ambitious goal. This framework encompasses three steps: controlling inflammation; resetting the immune system through elimination of pathogenic immune memory cells; and promoting and maintaining immune homeostasis via immune regulatory agents and tissue repair. We discuss existing drugs and those in development for each of the three steps. We also highlight the importance of causal human biology in identifying and prioritizing novel immunotherapeutic strategies as well as informing their application in specific patient subsets, enabling precision medicine approaches that have the potential to transform clinical care.

摘要

尽管在过去二十年中,自身免疫性疾病的治疗取得了重大进展,但大多数疗法并不能治愈疾病,而且由于广泛抑制免疫系统,可能会增加感染的风险。然而,对自身免疫性疾病病因的认识的进步,以及嵌合抗原受体 T 细胞疗法等新型治疗模式的临床数据,为我们提供了这样一种可能,即重建免疫系统的平衡,并有可能延长缓解期,甚至治愈自身免疫性疾病。在这里,我们提出了一种“序贯免疫疗法”的框架来调节免疫系统,以帮助实现这一雄心勃勃的目标。该框架包含三个步骤:控制炎症;通过消除致病性免疫记忆细胞来重置免疫系统;通过免疫调节药物和组织修复来促进和维持免疫平衡。我们讨论了每一步骤中现有的药物和正在开发的药物。我们还强调了在确定和优先考虑新型免疫治疗策略以及为特定患者群体提供信息方面,因果生物学的重要性,这使我们能够采用精准医疗方法,有可能改变临床护理。

相似文献

[1]
Sequential immunotherapy: towards cures for autoimmunity.

Nat Rev Drug Discov. 2024-7

[2]
Engineering antigen-presenting cells for immunotherapy of autoimmunity.

Adv Drug Deliv Rev. 2024-7

[3]
Design of effective immunotherapy for human autoimmunity.

Nature. 2005-6-2

[4]
Treating human autoimmunity: current practice and future prospects.

Sci Transl Med. 2012-3-14

[5]
Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.

Trends Immunol. 2019-10-7

[6]
Regulatory dendritic cells in autoimmunity: A comprehensive review.

J Autoimmun. 2015-8-5

[7]
Nanoparticle-based autoimmune disease therapy.

Clin Immunol. 2015-9

[8]
Innate immune cells for immunotherapy of autoimmune and cancer disorders.

Int Rev Immunol. 2017-9-21

[9]
Novel delivery mechanisms for antigen-specific immunotherapy.

Curr Opin Endocrinol Diabetes Obes. 2021-8-1

[10]
Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?

Cell Immunol. 2020-12

引用本文的文献

[1]
Editorial: Community series in pathogenetic mechanism and therapeutic target for inflammation in autoimmune disease, volume II.

Front Immunol. 2025-7-18

[2]
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges.

Front Immunol. 2025-7-11

[3]
Smart responsive biomaterials for spatiotemporal modulation of functional tissue repair.

Mater Today Bio. 2025-7-9

[4]
SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges.

Front Immunol. 2025-7-3

[5]
Proteome-Wide Mendelian Randomization Identifies Candidate Causal Proteins for Cardiovascular Diseases.

Adv Genet (Hoboken). 2025-3-10

[6]
Serum tryptophan-kynurenine metabolites served as biomarkers of disease activity in rheumatoid arthritis and linked to immune imbalance.

Arthritis Res Ther. 2025-7-5

[7]
The complement system in autoimmune diseases: pathogenesis, diagnostic markers, and therapeutic strategies.

Inflamm Res. 2025-6-30

[8]
Risk factors for persistent infection of high-risk HPV in patients with cervical intraepithelial neoplasia.

Am J Transl Res. 2025-4-15

[9]
Selenium-Binding Protein 1-Deficient Dendritic Cells Protect Mice from Sepsis by Increased Treg/Th17.

Antioxidants (Basel). 2025-4-14

[10]
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma.

Leukemia. 2025-4-24

本文引用的文献

[1]
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

JCI Insight. 2024-2-8

[2]
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

N Engl J Med. 2024-2-22

[3]
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Lancet. 2024-3-2

[4]
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.

Lancet. 2024-3-2

[5]
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.

Lancet Rheumatol. 2020-3

[6]
Thymic stromal lymphopoietin induces IL-4/IL-13 from T cells to promote sebum secretion and adipose loss.

J Allergy Clin Immunol. 2024-8

[7]
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Front Immunol. 2023

[8]
Anti-CD19 CAR T cells for refractory myasthenia gravis.

Lancet Neurol. 2023-12

[9]
Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.

Cell. 2023-11-9

[10]
Targeted depletion of TRBV9 T cells as immunotherapy in a patient with ankylosing spondylitis.

Nat Med. 2023-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索